BR9809330A - Halotherapy development process - Google Patents

Halotherapy development process

Info

Publication number
BR9809330A
BR9809330A BR9809330-4A BR9809330A BR9809330A BR 9809330 A BR9809330 A BR 9809330A BR 9809330 A BR9809330 A BR 9809330A BR 9809330 A BR9809330 A BR 9809330A
Authority
BR
Brazil
Prior art keywords
powder
halotherapy
dispenser
dosage
user
Prior art date
Application number
BR9809330-4A
Other languages
Portuguese (pt)
Inventor
Valentin Antonovich Vinogradov
Robert Stanley Dirksing
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority claimed from PCT/US1998/008372 external-priority patent/WO1998048875A1/en
Publication of BR9809330A publication Critical patent/BR9809330A/en

Links

Abstract

Patente de Invenção: <B>"PROCESSO DE DESENVOLVIMENTO DE HALOTERAPIA"<D>. Processo para prover a haloterapia à parte superior (22-26) do trato respiratório inferior (20), o qual inclui as etapas de operação de um dispensador (30) e de inalação. O dispensador (30) contém um pó de cloreto de sódio seco. O usuário opera o dispensador (30) para liberar uma dosagem de pó para inalação, quando o dispensador (30) for direcionado para a boca do usuário. O usuário inala então a dosagem de pó através da boca. Devido ao fato de o pó apresentar uma faixa de tamanho de partícula que permite que o pó atinja a parte superior (22-26) do trato respiratório inferior (20) sem ser introduzido nos pulmões do usuário, a dosagem do pó seco apresenta uma concentração na parte superior (22-26) suficiente para prover a eficaz haloterapia. O tamanho de partícula preferido é de cerca de 5 mícrons a cerca de 20 mícrons. A dosagem preferida é de cerca de 3 miligramas de pó.Invention Patent: <B> "HALOTHERAPY DEVELOPMENT PROCESS" <D>. Process for providing halotherapy to the upper part (22-26) of the lower respiratory tract (20), which includes the steps of operating a dispenser (30) and inhalation. The dispenser (30) contains a dry sodium chloride powder. The user operates the dispenser (30) to release a dosage of powder for inhalation when the dispenser (30) is directed to the user's mouth. The user then inhales the powder dosage through the mouth. Due to the fact that the powder has a particle size range that allows the powder to reach the upper part (22-26) of the lower respiratory tract (20) without being introduced into the user's lungs, the dry powder dosage presents a concentration at the top (22-26) enough to provide effective halotherapy. The preferred particle size is about 5 microns to about 20 microns. The preferred dosage is about 3 milligrams of powder.

BR9809330-4A 1997-04-29 1998-04-29 Halotherapy development process BR9809330A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81413297A 1997-04-29 1997-04-29
PCT/US1998/008372 WO1998048875A1 (en) 1997-04-29 1998-04-29 Method of delivering halotherapy

Publications (1)

Publication Number Publication Date
BR9809330A true BR9809330A (en) 2000-07-04

Family

ID=25214258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809330-4A BR9809330A (en) 1997-04-29 1998-04-29 Halotherapy development process

Country Status (1)

Country Link
BR (1) BR9809330A (en)

Similar Documents

Publication Publication Date Title
CA2210717C (en) An inhaler
AU612333B2 (en) Inhalation device
IS1796B (en) Inhaled polypeptide formulation composition which also contains an enhancer compound
BR9814928A (en) Inhalation device for administering powdered medication
NZ507151A (en) Pulmonary and nasal delivery of raloxifene
IS1768B (en) Inhalant pharmaceutical composition containing insulin
NO995251L (en) Method of administration of halotherapy
NO950368D0 (en) inhaler
US20120174917A1 (en) Press-type medical nebulizer and pressing means thereof
EA013180B1 (en) Improvement of a dry powder inhaler
ATE240759T1 (en) MEDICINAL ADMINISTRATION AND PACKAGING
CA2614628A1 (en) Inhalation device with a bottom surface formed as a foot
BR0017519B8 (en) medicine capsule for an inhaler, and process for manufacturing a capsule comprising a powdered medicine.
BR0107304A (en) Inhalation powder containing tiotropium
YU56600A (en) Device for delivering an active agent to the lung of a human patient
ES2179831T3 (en) RELEASE IN THE LUNGS OF ACTIVE FRAGMENTS OF PARTIROIDIAN HORMONE.
TW200607538A (en) Medicament inhaler device
ZA200710957B (en) Inhalator capsules
MX9704544A (en) Therapeutic preparation for inhalation containing parathyroid hormone, pth.
EP1224003B8 (en) Combination mouthpiece for inhalation therapy devices used by oxygen dependent patients
BR9809330A (en) Halotherapy development process
NO993540L (en) New formulation for inhalation having bulk density at a slope of 0.28 to 0.38 g / ml, comprising tebutaline sulfate, a process for the preparation of the formulation and its use
JPH05123398A (en) Throat protection inhalation agent and inhalation instrument
CA2465266C (en) Inhalation device for dry powder controlled by inspiration
KR102280232B1 (en) mask

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law